The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biologics May Prevent Cardiovascular Events in RA Patients

Biologics May Prevent Cardiovascular Events in RA Patients

August 26, 2020 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ajt/shutterstock.com

ajt/shutterstock.com

Introduction & Objectives
Patients with rheumatoid arthritis (RA) experience a higher rate of cardiovascular disease (CVD) events than controls. Chronic inflammation contributes to this risk. Indeed, RA patients with greater cumulative inflammation experience higher CVD event rates, and a reduction in RA inflammation associates with lower risk. Karpouzas et al. previously reported that RA disease activity is associated with greater coronary plaque burden and plaque vulnerability. Cumulative inflammation also predicts coronary plaque progression in RA patients. And subclinical coronary plaque burden is associated with mid-term CVD events in RA patients above and beyond what traditional risk factors or the cardiovascular Framingham Risk Score (FRS) would suggest. This suggested to researchers that sustained control of inflammation with the use of biologics may lower the CVD risk in patients with RA by inhibiting coronary plaque progression.

You Might Also Like
  • Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
Explore This Issue
October 2020

Thus, Karpouzas et al. set out to evaluate whether biologics decrease the CVD risk in RA patients and whether biologics have a beneficial effect on coronary plaque formation or progression.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods
In this single-center, observational cohort study, 150 patients underwent computed tomographic angiography for evaluation of coronary atherosclerosis (total, noncalcified, mixed/calcified, and low-attenuation plaque); 101 had repeat assessments within a mean ± SD of 6.9 ± 0.3 years to evaluate plaque progression. All CVD events were prospectively recorded, including cardiac death, myocardial infarction, unstable angina, revascularization, stroke, claudication and hospitalization for heart failure. The FRS was used to assess cardiovascular risk. The segment stenosis score was used to measure plaque burden. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated.

Results
After adjustment for the segment stenosis score, the FRS, and time-varying Disease Activity Score in 28 joints using the C-reactive protein level using marginal structural models, biologic use was associated with lower long-term CVD risk (OR 0.15 [95% CI 0.04–0.60]). Noncalcified and low-attenuation plaque presence moderated the effect of biologics on CVD risk. Specifically, biologic use was associated with lower CVD risk in patients with noncalcified or low-attenuation plaque at baseline (OR 0.21 [95% CI 0.04–0.99] and OR 0.08 [95% CI 0.01–0.70], respectively), but not in those without noncalcified or low-attenuation plaque. Per-segment plaque progression analyses showed that exposure to biologics was associated with transition of noncalcified to mixed/calcified plaque (OR 4.00 [95% CI 1.05–15.32]). Exposure to biologics predicted a lower likelihood of new plaque forming in segments without plaque among patients without mixed/calcified plaque in other coronary segments (OR 0.40 [95% CI 0.17–0.93]), but not among those with calcification. Biologic treatment also predicted low-attenuation plaque loss (P=0.042).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, DMARDs & Immunosuppressives, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, biologic DMARD, Cardiovascular disease, CVD, Rheumatoid Arthritis (RA)Issue: October 2020

You Might Also Like:
  • Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.